SUHENDANEKMEKCIOGLUSUHENDAN EKMEKCIOGLU8646EKMEKCIOGLU, SUHENDANProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1515 Holcombe BlvdHouston77030-4009TXAuthorship 1662528Authorship 1682376Authorship 1689681Authorship 1719042Authorship 1756352Authorship 1760517Authorship 1793952Authorship 1815944Authorship 1818036Authorship 1838315Authorship 1844792Authorship 1884593Authorship 1906992Authorship 1909224Authorship 1920783Authorship 19484357595752Kebudi R, Ayan I, Darendeliler E, Agaoglu L, Ekmek?ioglu S, Yagci T, Piskin S, Bilge NJournal of neuro-oncologyImmunologic status in children with brain tumors and the effect of therapy. J Neurooncol. 1995; 24(3):219-27.J Neurooncol1995-01-01T00:00:001995Immunologic status in children with brain tumors and the effect of therapy.10089074Ayan I, Luca JW, Jaffe N, Yazici H, Ekmek?ioglu S, Hansen MFJournal of experimental & clinical cancer research : CRGermline mutations of the p53 gene in children with malignant solid tumors. J Exp Clin Cancer Res. 1998 Dec; 17(4):497-502.J Exp Clin Cancer Res1998-12-01T00:00:001998Germline mutations of the p53 gene in children with malignant solid tumors.12481423Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AMMolecular cancer therapeuticsA novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther. 2002 Oct; 1(12):1009-17.Mol Cancer Ther2002-10-01T00:00:002002A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide.15179184Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EAMelanoma researchInhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res. 2004 Jun; 14(3):165-71.Melanoma Res2004-06-01T00:00:002004Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells.16474847Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EAOncogeneRegulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene. 2006 Jun 29; 25(28):3956-62.Oncogene2006-02-13T00:00:002006Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.16710719Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Sutton RB, Poindexter N, Grimm EA, Chada SCancer immunology, immunotherapy : CIIHuman interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother. 2007 Feb; 56(2):205-15.Cancer Immunol Immunother2006-05-19T00:00:002006Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.17238830Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm EAJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine ResearchSoluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res. 2006 Dec; 26(12):877-86.J Interferon Cytokine Res2006-12-01T00:00:002006Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes.19056673Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada SMolecular cancer therapeuticsInterleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008 Dec; 7(12):3842-51.Mol Cancer Ther2008-12-03T00:00:002008Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.20975100Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EAClinical cancer research : an official journal of the American Association for Cancer ResearchClinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35.Clin Cancer Res2010-10-25T00:00:002010Clinical correlates of NRAS and BRAF mutations in primary human melanoma.21954434Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Liz?e G, Poindexter N, Grimm EAMolecular cancer research : MCRConstitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res. 2011 Nov; 9(11):1537-50.Mol Cancer Res2011-09-27T00:00:002011Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma.23293541Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KBClinical pharmacology : advances and applicationsArginine deprivation therapy for malignant melanoma. Clin Pharmacol. 2013; 5:11-9.Clin Pharmacol2012-12-27T00:00:002012Arginine deprivation therapy for malignant melanoma.LeukemiaMelanoma Medical OncologySurgical OncologyMD AndersonJEFFREY EGERSHENWALDJEFFREY E GERSHENWALD8667GERSHENWALD, JEFFREY EProfessorJENNIFERWARGOJENNIFER WARGO9904WARGO, JENNIFERAssociate Professor2.291460.00595221322research areas6.292150.010200781coauthor of50.011810.732260similar to1182selected publicationsJARED KBURKSJARED K BURKS9429BURKS, JARED KAssistant ProfessorELIZABETH AGRIMMELIZABETH A GRIMM8484GRIMM, ELIZABETH AProfessorMICHAEL ADAVIESMICHAEL A DAVIES8753DAVIES, MICHAEL AAssociate ProfessorVICTORPRIETOVICTOR PRIETO8828PRIETO, VICTORProfessorPATRICKHWUPATRICK HWU9108HWU, PATRICKProfessorGREGORY ALIZEEGREGORY A LIZEE9130LIZEE, GREGORY AAssociate ProfessorAuthorship 2194221Authorship 2214323Authorship 2220981Authorship 2234762Authorship 2296491Authorship 2327403Authorship 235012911668478Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EAInternational journal of cancerDown-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer. 2001 Oct 01; 94(1):54-9.Int J Cancer2001-10-01T00:00:002001Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas.15120650Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Po?ndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AMInternational immunopharmacologyMDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004 May; 4(5):649-67.Int Immunopharmacol2004-05-01T00:00:002004MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family.16557582Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EAInternational journal of cancerTumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006 Aug 15; 119(4):861-6.Int J Cancer2006-08-15T00:00:002006Tumor iNOS predicts poor survival for stage III melanoma patients.16818508Fok JY, Ekmekcioglu S, Mehta KMolecular cancer therapeuticsImplications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther. 2006 Jun; 5(6):1493-503.Mol Cancer Ther2006-06-01T00:00:002006Implications of tissue transglutaminase expression in malignant melanoma.21745040Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A, Newman RA, Grimm EANutrition and cancerZyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutr Cancer. 2011; 63(6):940-9.Nutr Cancer2011-07-11T00:00:002011Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells.23020131Qin Y, Deng W, Ekmekcioglu S, Grimm EAPigment cell & melanoma researchIdentification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell Melanoma Res. 2013 Jan; 26(1):97-112.Pigment Cell Melanoma Res2012-11-06T00:00:002012Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening.24574257Wang Y, Hu S, Gabisi AM, Er JA, Pope A, Burstein G, Schardon CL, Cardounel AJ, Ekmekcioglu S, Fast WChemMedChemDeveloping an irreversible inhibitor of human DDAH-1, an enzyme upregulated in melanoma. ChemMedChem. 2014 Apr; 9(4):792-7.ChemMedChem2014-02-26T00:00:002014Developing an irreversible inhibitor of human DDAH-1, an enzyme upregulated in melanoma.Authorship 2410333Authorship 2436791Authorship 2446891Authorship 24559013Authorship 2462609Authorship 2476761Authorship 2507361Authorship 2514904Authorship 2534123Authorship 2576533Authorship 25800813Authorship 25831839578838Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, Grimm EA, Roth JAGene therapySuppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. 1998 Feb; 5(2):189-95.Gene Ther1998-02-01T00:00:001998Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide.11156233Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EAClinical cancer research : an official journal of the American Association for Cancer ResearchInducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000 Dec; 6(12):4768-75.Clin Cancer Res2000-12-01T00:00:002000Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.12533668Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EAMolecular cancer therapeuticsNegative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther. 2003 Jan; 2(1):9-17.Mol Cancer Ther2003-01-01T00:00:002003Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells.15564140Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu SMolecular therapy : the journal of the American Society of Gene TherapyBystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004 Dec; 10(6):1085-95.Mol Ther2004-12-01T00:00:002004Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.15585417Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada SMolecular therapy : the journal of the American Society of Gene TherapyIntratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan; 11(1):160-72.Mol Ther2005-01-01T00:00:002005Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.15810875Ekmekcioglu S, Tang CH, Grimm EACurrent cancer drug targetsNO news is not necessarily good news in cancer. Curr Cancer Drug Targets. 2005 Mar; 5(2):103-15.Curr Cancer Drug Targets2005-03-01T00:00:002005NO news is not necessarily good news in cancer.18472017Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu SNitric oxide : biology and chemistryConstitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide. 2008 Sep; 19(2):133-7.Nitric Oxide2008-04-22T00:00:002008Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis.18511292Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EACytokineKilling of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine. 2008 Jul; 43(1):34-44.Cytokine2008-06-03T00:00:002008Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.20216471Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EAMelanoma researchIL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res. 2011 Feb; 21(1):44-56.Melanoma Res2011-02-01T00:00:002011IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.21953496Tanese K, Grimm EA, Ekmekcioglu SInternational journal of cancerThe role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer. 2012 Aug 15; 131(4):891-901.Int J Cancer2011-10-23T00:00:002011The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10.22020736Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EAInternational journal of cancerAssociation of activated c-Met with NRAS-mutated human melanomas. Int J Cancer. 2012 Jul 15; 131(2):E56-65.Int J Cancer2012-01-11T00:00:002012Association of activated c-Met with NRAS-mutated human melanomas.22850568Khalili JS, Liu S, Rodr?guez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Liz?e GClinical cancer research : an official journal of the American Association for Cancer ResearchOncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40.Clin Cancer Res2012-07-31T00:00:002012Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.Authorship 270712223190886Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MGThe Journal of investigative dermatologyThe TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol. 2013 Apr; 133(4):1052-62.J Invest Dermatol2012-11-29T00:00:002012The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.Authorship 278527259Authorship 2896883Authorship 2901314Authorship 2935024Authorship 2969557Authorship 29928118Authorship 303904724752867Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock RCancerDual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73.Cancer2014-04-17T00:00:002014Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.24969538Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff VTranslational oncologyCharacterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol. 2014 Aug; 7(4):484-92.Transl Oncol2014-06-23T00:00:002014Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.25546243Qin Y, Milton DR, Oba J, Ding Z, Liz?e G, Ekmekcioglu S, Grimm EAPigment cell & melanoma researchInflammatory IL-1?-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res. 2015 Mar; 28(2):236-9.Pigment Cell Melanoma Res2015-01-12T00:00:002015Inflammatory IL-1?-driven JNK activation in stage III melanoma.26039541Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EAThe Journal of investigative dermatologyCell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2775-2784.J Invest Dermatol2015-06-03T00:00:002015Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?.26178706Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EAThe Journal of investigative dermatologyCell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2901.J Invest Dermatol2015-07-16T00:00:002015Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?.26450788Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin LCancer discoveryDual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27.Cancer Discov2015-10-08T00:00:002015Dual Roles of RNF2 in Melanoma Progression.74Professor10Assistant Professor14Associate ProfessorHUSSEINTAWBIHUSSEIN TAWBI11940TAWBI, HUSSEINAssociate Professor22966490Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, B?nhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, B?chet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahov? M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronj? MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, D?az-Araya G, D?az-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farr? JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, F?s?s L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et alAutophagyGuidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.Autophagy2012-04-01T00:00:002012Guidelines for the use and interpretation of assays for monitoring autophagy.20215556Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WWClinical cancer research : an official journal of the American Association for Cancer ResearchTargeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44.Clin Cancer Res2010-03-09T00:00:002010Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.Authorship 841992Authorship 845784Authorship 846723Authorship 846757Authorship 847072Authorship 848999Authorship 849729Authorship 852818Authorship 856321Authorship 856865Authorship 859744Authorship 861770Authorship 862613Authorship 863801Authorship 863976Authorship 86417428254151Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WWNeoplasia (New York, N.Y.)Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia. 2017 03; 19(3):237-249.Neoplasia2017-03-01T00:00:002017Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.Hematopoietic Growth Factors and Cytokines. Hematopoietic Growth Factors and CytokinesTranslational OncologyCharacterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7:484-492.Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumorsJournal of Investigative DermatologyErratum. Journal of Investigative Dermatology. 135:2775-2784.ErratumClinical Cancer ResearchInflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clinical Cancer Research. 22:3016-3024.Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanomaNeoplasia (United States)Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia (United States). Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' TumorInternational Journal of Experimental and Clinical ChemotherapyRadioprotective effect of rat serum induced by lectins in mice. International Journal of Experimental and Clinical Chemotherapy. 3:115-119.Radioprotective effect of rat serum induced by lectins in miceJournal of Investigative DermatologyCell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ (Journal of Investigative Dermatology (2015) 135 (2901) DOI. Journal of Investigative Dermatology. 135:2901.Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ (Journal of Investigative Dermatology (2015) 135 (2901) DOIMolecular Cancer TherapeuticsHypoxia-driven mechanism of vemurafenib resistance in melanoma. Molecular Cancer Therapeutics. 15:2442-2454.Hypoxia-driven mechanism of vemurafenib resistance in melanomaScientific ReportsExploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 6.Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinomaForum on Immunopathological Diseases and TherapeuticsBraf mutations are associated with high levels of phosphorylated RKIP in melanoma cell lines. Forum on Immunopathological Diseases and Therapeutics. 2:189-194.Braf mutations are associated with high levels of phosphorylated RKIP in melanoma cell linesPigment Cell and Melanoma ResearchMicrosomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell and Melanoma Research. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progressionJournal of DermatologyCase of squamous cell carcinoma showing delayed metastasis and histologically exhibiting alterations of the surrounding immune cell populations along with the tumor invasion. Journal of Dermatology. Case of squamous cell carcinoma showing delayed metastasis and histologically exhibiting alterations of the surrounding immune cell populations along with the tumor invasionClinical Cancer ResearchClinical correlates of NRAS and BRAF mutations in primary human melanoma (Clinical Cancer Research (2011) 17 (229-235)). Clinical Cancer Research. 17:1641.Clinical correlates of NRAS and BRAF mutations in primary human melanoma (Clinical Cancer Research (2011) 17 (229-235))Hematopoietic Growth Factors and Cytokines. 605-619.Hematopoietic Growth Factors and CytokinesRadioprotective effect of rat serum stimulated by some stimulants in mice in which irradiation of the total body with lethal doses was administered. 29-36.Radioprotective effect of rat serum stimulated by some stimulants in mice in which irradiation of the total body with lethal doses was administeredCancer DiscoveryDual roles of RNF2 in melanoma progression. Cancer Discovery. 5:1314-1327.Dual roles of RNF2 in melanoma progression10465582Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-Schaub L, Buzaid AC, Grimm EAMelanoma researchDifferential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res. 1999 Jun; 9(3):261-72.Melanoma Res1999-06-01T00:00:001999Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10.18626307Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KBMelanoma researchChanges in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5.Melanoma Res2008-08-01T00:00:002008Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.Authorship 8878988D000949Chemicals & Drugs1231820.924083Histocompatibility Antigens Class IID052247Chemicals & Drugs1312610.906078Nitric Oxide Synthase Type IID019746Chemicals & Drugs46810.939689Intramolecular OxidoreductasesAuthorship 9041629Authorship 9044111Authorship 9049119Authorship 9114057Authorship 9119758Authorship 9130491Authorship 9140876Authorship 9186462Authorship 9313808Authorship 9321437Authorship 9329143Authorship 9350074Authorship 937923526801201Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EAPigment cell & melanoma researchMicrosomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res. 2016 May; 29(3):297-308.Pigment Cell Melanoma Res2016-03-15T00:00:002016Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.26783288Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EAClinical cancer research : an official journal of the American Association for Cancer ResearchInflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.Clin Cancer Res2016-01-18T00:00:002016Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.27458138Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EAMolecular cancer therapeuticsHypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454.Mol Cancer Ther2016-07-25T00:00:002016Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.27667796Tanese K, Funakoshi T, Yasuda F, Ohi Y, Fukuyama M, Arakawa H, Ekmekcioglu S, Saito MThe Journal of dermatologyCase of squamous cell carcinoma showing delayed metastasis and histologically exhibiting alterations of the surrounding immune cell populations along with the tumor invasion: Expression of monocyte chemotactic protein-1 in deeply invaded tumor cells and interleukin-6 in surrounding histiocytes. J Dermatol. 2017 Mar; 44(3):346-348.J Dermatol2016-09-26T00:00:002016Case of squamous cell carcinoma showing delayed metastasis and histologically exhibiting alterations of the surrounding immune cell populations along with the tumor invasion: Expression of monocyte chemotactic protein-1 in deeply invaded tumor cells and interleukin-6 in surrounding histiocytes.28121247Ekmekcioglu S, Grimm EA, Roszik JHuman vaccines & immunotherapeuticsTargeting iNOS to increase efficacy of immunotherapies. Hum Vaccin Immunother. 2017 05 04; 13(5):1105-1108.Hum Vaccin Immunother2017-01-25T00:00:002017Targeting iNOS to increase efficacy of immunotherapies.27762323Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik JScientific reportsExploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep. 2016 10 20; 6:35848.Sci Rep2016-10-20T00:00:002016Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.28670312Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik JFrontiers in immunologyCervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689.Front Immunol2017-06-16T00:00:002017Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.28681540Baba Y, Funakoshi T, Mori M, Emoto K, Masugi Y, Ekmekcioglu S, Amagai M, Tanese KJournal of the European Academy of Dermatology and Venereology : JEADVExpression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma. J Eur Acad Dermatol Venereol. 2017 Dec; 31(12):2038-2045.J Eur Acad Dermatol Venereol2017-08-06T00:00:002017Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma.29616189Kim SH, Roszik J, Grimm EA, Ekmekcioglu SFrontiers in oncologyImpact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. Front Oncol. 2018; 8:67.Front Oncol2018-03-16T00:00:002018Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy.30254633Roszik J, Tanese K, Ekmekcioglu SFrontiers in immunologyEditorial: Targeting Metabolism in Cancer Immunotherapy. Front Immunol. 2018; 9:2029.Front Immunol2018-09-11T00:00:002018Editorial: Targeting Metabolism in Cancer Immunotherapy.30256441Dal Yontem F, Kim SH, Ding Z, Grimm E, Ekmekcioglu S, Akcakaya HJournal of cellular biochemistryMitochondrial dynamic alterations regulate melanoma cell progression. J Cell Biochem. 2018 Sep 06.J Cell Biochem2018-09-06T00:00:002018Mitochondrial dynamic alterations regulate melanoma cell progression.30652536Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik JJCO clinical cancer informaticsHigh-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 12; 2:1-12.JCO Clin Cancer Inform2018-12-01T00:00:002018High-Throughput Architecture for Discovering Combination Cancer Therapeutics.30538110Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EAClinical cancer research : an official journal of the American Association for Cancer ResearchThe COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. 2019 03 01; 25(5):1650-1663.Clin Cancer Res2018-12-11T00:00:002018The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.D008545Disorders68053010.290119MelanomaD007378Chemicals & Drugs1633250.810934InterleukinsPathologyAuthorship 1007003933327409Ogata D, Roszik J, Oba J, Kim SH, Bassett RL, Haydu LE, Tanese K, Grimm EA, Ekmekcioglu SCancersThe Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. Cancers (Basel). 2020 Dec 14; 12(12).Cancers (Basel)2020-12-14T00:00:002020The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival.Authorship 1008519633418925Ahmed R, Muralidharan R, Srivastava A, Johnston SE, Zhao YD, Ekmekcioglu S, Munshi A, Ramesh RCancersMolecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells. Cancers (Basel). 2021 Jan 06; 13(2).Cancers (Basel)2021-01-06T00:00:002021Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells.Authorship 1012527933643925Ding Z, Ogata D, Roszik J, Qin Y, Kim SH, Tetzlaff MT, Lazar AJ, Davies MA, Ekmekcioglu S, Grimm EAFrontiers in oncologyiNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Front Oncol. 2021; 11:631766.Front Oncol2021-02-12T00:00:002021iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation.Authorship 1013496833686688Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RNCancer medicineThe efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med. 2021 04; 10(7):2293-2299.Cancer Med2021-03-08T00:00:002021The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.Authorship 10393931135121729Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu SCell death & diseaseInterplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 02 04; 13(2):117.Cell Death Dis2022-02-04T00:00:002022Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma.Authorship 10449761135501311Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu SCell death & diseaseCorrection: Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 May 02; 13(5):422.Cell Death Dis2022-05-02T00:00:002022Correction: Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma.Authorship 10457413635537412Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab ACancer cellInterleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.Cancer Cell2022-05-09T00:00:002022Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.Authorship 10791451037529399Fukuda Y, Kim SH, Bustos MA, Cho SN, Roszik J, Burks JK, Kim H, Hoon DSB, Grimm EA, Ekmekcioglu SCancer research communicationsInhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun. 2023 07; 3(7):1397-1408.Cancer Res Commun2023-07-31T00:00:002023Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion.Authorship 10898502238418901Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HANature communicationsComprehensive characterization of IFN? signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun. 2024 Feb 28; 15(1):1821.Nat Commun2024-02-28T00:00:002024Comprehensive characterization of IFN? signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professor23868870Grimm EA, Sikora AG, Ekmekcioglu SClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res. 2013 Oct 15; 19(20):5557-63.Clin Cancer Res2013-07-18T00:00:002013Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.24398473Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AGCancer researchInducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 2014 Feb 15; 74(4):1067-78.Cancer Res2014-01-07T00:00:002014Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.